Rosetta Genomics, Ltd.
10 Plaut Street
Science Park
Rehovot,
76706
Israel - Map
Phone: 972 73 222 0700
Fax: 972 73 222 0701
Web Site: http://www.rosettagenomics.com
| Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the companys microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Isaac Bentwich M.D., 48
Founder, Chief Architect |
$
312.00K | N/A | Mr. Kenneth A. Berlin , 45
Chief Exec. Officer and Pres |
N/A
| N/A | Ms. Limor Zur-Stoller , 39
Principal Accounting & Financial Officer and VP of Fin. |
N/A
| N/A | Prof. Zvi Bentwich M.D.,
Deputy Chairman of the Scientific Advisory Board |
N/A
| N/A | Dr. Ranit Aharonov Ph.D., 40
Head of Computational Biology and Exec. VP of R&D
|
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
0.05 (2.44%) 
Profile
